May 23, 2018 / 12:32 PM / 3 months ago

BRIEF-FDA Grants Breakthrough Therapy Designation For Pfizer's Tafamidis

May 23 (Reuters) - Pfizer Inc:

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR TAFAMIDIS FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY

* PFIZER INC - DECISION IS SUPPORTED BY TOPLINE RESULTS FROM TAFAMIDIS PHASE 3 TRANSTHYRETIN CARDIOMYOPATHY (ATTR-ACT) STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below